The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer

Waseem Ashraf; Abdulkhaleg Ibrahim; Mahmoud Alhosin; Liliyana Zaayter; Khalid Ouararhni; Christophe Papin; Tanveer Ahmad; Ali Hamiche; Yves Mély; Christian Bronner; Marc Mousli

doi:10.18632/oncotarget.17393

The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer

Waseem Ashraf, Abdulkhaleg Ibrahim, Mahmoud Alhosin, Liliyana Zaayter, Khalid Ouararhni, Christophe Papin, Tanveer Ahmad, Ali Hamiche, Yves Mély, Christian Bronner, Marc Mousli^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

89 Citations (Scopus)

Abstract

Cancer is one of the deadliest diseases in the world causing record number of mortalities in both developed and undeveloped countries. Despite a lot of advances and breakthroughs in the field of oncology still, it is very hard to diagnose and treat the cancers at early stages. Here in this review we analyze the potential of Ubiquitinlike containing PHD and Ring Finger domain 1 (UHRF1) as a universal biomarker for cancers. UHRF1 is an important epigenetic regulator maintaining DNA methylation and histone code in the cell. It is highly expressed in a variety of cancers and is a wellknown oncogene that can disrupt the epigenetic code and override the senescence machinery. Many studies have validated UHRF1 as a powerful diagnostic and prognostic tool to differentially diagnose cancer, predict the therapeutic response and assess the risk of tumor progression and recurrence. Highly sensitive, non-invasive and cost effective approaches are therefore needed to assess the level of UHRF1 in patients, which can be deployed in diagnostic laboratories to detect cancer and monitor disease progression.

Original language	English
Pages (from-to)	51946-51962
Number of pages	17
Journal	Oncotarget
Volume	8
Issue number	31
DOIs	https://doi.org/10.18632/oncotarget.17393
Publication status	Published - 7 Feb 2017
Externally published	Yes

Keywords

Biomarkers
Cancer
DNA methylation
Epigenetics
UHRF1

Access to Document

10.18632/oncotarget.17393

Cite this

@article{715524f5099c41108308c8d3c0b5fc39,

title = "The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer",

abstract = "Cancer is one of the deadliest diseases in the world causing record number of mortalities in both developed and undeveloped countries. Despite a lot of advances and breakthroughs in the field of oncology still, it is very hard to diagnose and treat the cancers at early stages. Here in this review we analyze the potential of Ubiquitinlike containing PHD and Ring Finger domain 1 (UHRF1) as a universal biomarker for cancers. UHRF1 is an important epigenetic regulator maintaining DNA methylation and histone code in the cell. It is highly expressed in a variety of cancers and is a wellknown oncogene that can disrupt the epigenetic code and override the senescence machinery. Many studies have validated UHRF1 as a powerful diagnostic and prognostic tool to differentially diagnose cancer, predict the therapeutic response and assess the risk of tumor progression and recurrence. Highly sensitive, non-invasive and cost effective approaches are therefore needed to assess the level of UHRF1 in patients, which can be deployed in diagnostic laboratories to detect cancer and monitor disease progression.",

keywords = "Biomarkers, Cancer, DNA methylation, Epigenetics, UHRF1",

author = "Waseem Ashraf and Abdulkhaleg Ibrahim and Mahmoud Alhosin and Liliyana Zaayter and Khalid Ouararhni and Christophe Papin and Tanveer Ahmad and Ali Hamiche and Yves M{\'e}ly and Christian Bronner and Marc Mousli",

note = "Publisher Copyright: {\textcopyright} Ashraf et al.",

year = "2017",

month = feb,

day = "7",

doi = "10.18632/oncotarget.17393",

language = "English",

volume = "8",

pages = "51946--51962",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "31",

}

TY - JOUR

T1 - The epigenetic integrator UHRF1

T2 - On the road to become a universal biomarker for cancer

AU - Ashraf, Waseem

AU - Ibrahim, Abdulkhaleg

AU - Alhosin, Mahmoud

AU - Zaayter, Liliyana

AU - Ouararhni, Khalid

AU - Papin, Christophe

AU - Ahmad, Tanveer

AU - Hamiche, Ali

AU - Mély, Yves

AU - Bronner, Christian

AU - Mousli, Marc

N1 - Publisher Copyright: © Ashraf et al.

PY - 2017/2/7

Y1 - 2017/2/7

N2 - Cancer is one of the deadliest diseases in the world causing record number of mortalities in both developed and undeveloped countries. Despite a lot of advances and breakthroughs in the field of oncology still, it is very hard to diagnose and treat the cancers at early stages. Here in this review we analyze the potential of Ubiquitinlike containing PHD and Ring Finger domain 1 (UHRF1) as a universal biomarker for cancers. UHRF1 is an important epigenetic regulator maintaining DNA methylation and histone code in the cell. It is highly expressed in a variety of cancers and is a wellknown oncogene that can disrupt the epigenetic code and override the senescence machinery. Many studies have validated UHRF1 as a powerful diagnostic and prognostic tool to differentially diagnose cancer, predict the therapeutic response and assess the risk of tumor progression and recurrence. Highly sensitive, non-invasive and cost effective approaches are therefore needed to assess the level of UHRF1 in patients, which can be deployed in diagnostic laboratories to detect cancer and monitor disease progression.

AB - Cancer is one of the deadliest diseases in the world causing record number of mortalities in both developed and undeveloped countries. Despite a lot of advances and breakthroughs in the field of oncology still, it is very hard to diagnose and treat the cancers at early stages. Here in this review we analyze the potential of Ubiquitinlike containing PHD and Ring Finger domain 1 (UHRF1) as a universal biomarker for cancers. UHRF1 is an important epigenetic regulator maintaining DNA methylation and histone code in the cell. It is highly expressed in a variety of cancers and is a wellknown oncogene that can disrupt the epigenetic code and override the senescence machinery. Many studies have validated UHRF1 as a powerful diagnostic and prognostic tool to differentially diagnose cancer, predict the therapeutic response and assess the risk of tumor progression and recurrence. Highly sensitive, non-invasive and cost effective approaches are therefore needed to assess the level of UHRF1 in patients, which can be deployed in diagnostic laboratories to detect cancer and monitor disease progression.

KW - Biomarkers

KW - Cancer

KW - DNA methylation

KW - Epigenetics

KW - UHRF1

UR - http://www.scopus.com/inward/record.url?scp=85026786630&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17393

DO - 10.18632/oncotarget.17393

M3 - Review article

C2 - 28881702

AN - SCOPUS:85026786630

SN - 1949-2553

VL - 8

SP - 51946

EP - 51962

JO - Oncotarget

JF - Oncotarget

IS - 31

ER -

The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this